MarginsXMarginsX
Home › Markets › Health Care › ACTU

Actuate Therapeutics Inc. (ACTU)

ACTU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.2680
-7.59% on the day
Market cap
$14.7M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerACTU on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001652935
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
2.7 months
$4.4M cash at June 30, 2026
Share count, 1 year
+159.8%
2025-11-12 to 2026-11-13
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
-$1.6M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern. 2."
10-Q 2026-11-13
Cash and burn$4.4M cash; operating cash flow -$5.0M a quarter.Report 2026-06-30
Shares outstanding60,382,824 (2026-11-13); 23,243,328 a year earlier.Cover page 2026-11-13
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-10-28
Exchange deficiency notices, 12 months2 (8-K item 3.01)8-K 2026-10-30
AuditorCrowe LLP, Costa Mesa, California, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $1.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$4.9M-$4.4M$4.4MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$5.6M-$5.0M$8.1MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$4.6M-$3.7M$13.2MNo debt tagsNeeds four quarters10-K 2026-03-26
Q3 2025
2025-09-30
Not filed-$5.4M-$6.7M$16.9MNo debt tagsNeeds four quarters10-Q 2025-11-13
Q2 2025
2025-06-30
Not filed-$5.9M-$4.2M$6.5MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$6.3M-$4.6M$3.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$6.4M-$4.8M$8.6M$0Needs four quarters10-K 2026-03-26
Q3 2024
2024-09-30
Not filed-$6.0M-$9.1M$13.5M$0Needs four quarters10-Q 2025-11-13

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52026-10-28
Latest annual report
FORM 10-K FOR DEC 2025
10-K2026-03-26
Latest quarterly / interim
FORM 10-Q SEP 2026
10-Q2026-11-13
Latest current report
CURRENT REPORT
8-K2026-10-30
Latest proxy
ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS
DEFA14A2026-05-06

Source: SEC EDGAR submissions feed, 193 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.4%
1 month-38.8%
3 months-70.8%
Year to date-95.3%
1 year-95.2%
From 52-week high-96.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M
CNTXContext Therapeutics Inc.$0.1659-8.24%$15.2M
ALLRAllarity Therapeutics Inc.$0.8752-8.24%$13.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier